HER2 (ERBB2) TESTING SHOULD BE USED TO INFORM TREATMENT DECISIONS IN METASTATIC COLORECTAL CANCER¹

EGFR = epidermal growth factor receptor; HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer; NCCN = National Comprehensive Cancer Network^® (NCCN^®); PFS = progression-free survival; WT = wild type.

References: 1. Raghav KPS. The role of HER2 amplification testing in metastatic colorectal cancer. Clin Adv Hematol Oncol. 2018;16(11):720-722. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Colon Cancer V3.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed February 1, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Rectal Cancer V4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed February 1, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist. 2019;24(10):1395-1402. doi:10.1634/theoncologist.2018-0785 5. Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol. 2019;3:1-13. doi:10.1200/PO.18.00226